| European Medicines Agency - Eligible Group Status - COMP [Committee for Orphan Medicinal Products] - SAWP [Scientific Advice Working Party]. | 呼吸器
> 肺線維症 | 規制上のパートナーシップ
> 規制機関との連携 | Not specified | International | Rarely | 119039359117 |
| When new drugs are approved by the EU medicines agency, we work to represent patient interest with the health service and government agency responsible for approving the drug in Ireland and regulating pricing of new drugs. | 呼吸器
> 間質性肺疾患（ILD） | 規制上のパートナーシップ
> 規制機関との連携 | 5,000 | National | Sometimes | 119044171823 |
| Submission on Lutathera for reimbursement decision. | がん
> がん：神経内分泌腫瘍（NET） | 規制上のパートナーシップ
> 医療技術評価（HTA）および償還審査への参加 | 1,000 | National | Rarely | 119039308095 |
| We share the patient experience of living with a condition as part of the reimbursement process. | 神経筋
> 神経筋疾患：ほとんどのタイプ | 規制上のパートナーシップ
> 医療技術評価（HTA）および償還審査への参加 | 1,000 | National | Sometimes | 119047368493 |
| We submitted our support to the NCPE [National Centre for Pharmacoeconomics] for their appraisal of Lutathera [used to treat adults with certain unresectable or metastatic gastroenteropancreatic neuroendocrine tumors]. | がん
> がん：神経内分泌腫瘍（NET） | 規制上のパートナーシップ
> 医療技術評価（HTA）および償還審査への参加 | 100 | National | Rarely | 119051190597 |
| Drugs for ataxia are very rare, so we only make submissions as they become available. | 神経変性
> 運動失調 | 規制上のパートナーシップ
> マーケティング承認申請への貢献 | 1,000 | National | Rarely | 119020208311 |
| European Medicines Agency - Eligible Group Status - COMP [Committee for Orphan Medicinal Products] - SAWP [Scientific Advice Working Party]. | 呼吸器
> 肺線維症 | 規制上のパートナーシップ
> 政策立案者・規制当局との会議への出席・ファシリテーション | Not specified | International | Rarely | 119039359117 |
| Meetings with Government Representatives and Department of Health regarding the availability of certain DMTs [Disease-Modifying Therapies primarily used for multiple sclerosis and various autoimmune conditions (like rheumatoid arthritis)]. | 神経学的
> 多発性硬化症 | 規制上のパートナーシップ
> 政策立案者・規制当局との会議への出席・ファシリテーション | 10,000 | National | Regularly | 119074666617 |
| National organization is affiliated with European groups which attempt to have influence. | 全般的な健康状態
> ヘルスリテラシー | 規制上のパートナーシップ
> 他の医療擁護者と | 100 | National | Rarely | 119052876993 |
| Advocacy/public affairs messaging about improving reimbursement decision-making for drugs in Ireland. | がん
> がん：ほとんどの種類 | 政策と法律への影響
> 医療政策と法律に影響を与える | 10,000 | National | Rarely | 119063937918 |
| We have advocated for our members to our government representatives at yearly events where we have been invited to government buildings to present to an invited group. | 患者擁護
> 健康活動家 | 政策と法律への影響
> 公聴会やパブリックコンサルテーションに参加する | 5,000 | National | Rarely | 119047297038 |
| We have advocated for our members to our government representatives at yearly events where we have been invited to government buildings to present to an invited group. | 患者擁護
> 健康活動家 | 政策と法律への影響
> 国会議員や政治指導者を動員する | 5,000 | National | Rarely | 119047297038 |
| We advocate for the most efficient medicine to be available and reimbursed for heart failure patients. | ハート
> 心不全 | 政策と法律への影響
> 医療における障壁・異常への対処 | 5,000 | National | Sometimes | 119051411038 |
| When new drugs are approved by the EU medicines agency, we work to represent patient interest with the health service and government agency responsible for approving the drug in Ireland and regulating pricing of new drugs. | 呼吸器
> 間質性肺疾患（ILD） | 価格設定と手頃な価格の擁護
> 価格審査委員会の交渉に参加する | 5,000 | National | Sometimes | 119044171823 |
| Advocacy/public affairs messaging about improving reimbursement decision-making for drugs in Ireland. | がん
> がん：ほとんどの種類 | 価格設定と手頃な価格の擁護
> 製品の償還リスト/国家医薬品集への収載推進 | 10,000 | National | Rarely | 119063937918 |
| Equity of access: Public patients can wait a lot longer for access to meds approved by EMA [European Medicines Agency], versus private patients whose insurance companies reimburse. | 患者擁護
> 健康活動家 | アクセス経路の改善
> 医薬品・医療への公平なアクセスを促進する | 1,000 | National | Sometimes | 119044976833 |
| We advocate for the most efficient medicine to be available and reimbursed for heart failure patients. | ハート
> 心不全 | アクセス経路の改善
> 医薬品・医療への公平なアクセスを促進する | 5,000 | National | Sometimes | 119051411038 |
| Meetings with Government Representatives and Department of Health regarding the availability of certain DMTs [Disease-Modifying Therapies primarily used for multiple sclerosis and various autoimmune conditions (like rheumatoid arthritis)]. | 神経学的
> 多発性硬化症 | アクセス経路の改善
> 医薬品・医療への公平なアクセスを促進する | 10,000 | National | Regularly | 119074666617 |
| Equity of access: Public patients can wait a lot longer for access to meds approved by EMA [European Medicines Agency], versus private patients whose insurance companies reimburse. | 患者擁護
> 健康活動家 | アクセス経路の改善
> アクセスと管理における格差への対処 | 1,000 | National | Sometimes | 119044976833 |
| Drugs for ataxia are very rare, so we only make submissions as they become available. | 神経変性
> 運動失調 | アクセス経路の改善
> 希少・超希少疾患治療へのアクセス改善 | 1,000 | National | Rarely | 119020208311 |
| During the course of projects based on issues experienced by the community. | 消化器系
> IBD | エビデンスに基づく患者の意見
> 患者の体験談や生きた経験のナラティブを活用する | 5,000 | National | Sometimes | 119020296590 |
| We share the patient experience of living with a condition as part of the reimbursement process. | 神経筋
> 神経筋疾患：ほとんどのタイプ | エビデンスに基づく患者の意見
> 患者の体験談や生きた経験のナラティブを活用する | 1,000 | National | Sometimes | 119047368493 |
インタラクション
アクションと支援活動
9 メンション
